CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 105 enrolled
Drug / intervention
Etokimab +2 morebiological
Likely dose
Mometasone Furoate Nasal Spray 50 μgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03614923
NCT03614923Phase 2Completed
CompareCT.gov

A Phase 2, Double-Blind, Placebo-Controlled, Parallel Group, Multiple Dose Study to Investigate Etokimab (ANB020) in Adult Subjects With Chronic Rhinosinusitis With Nasal Polyposis

AnaptysBio, Inc.·interventional·Posted Aug 3, 2018·Updated Jan 24, 2022

In Brief

A Phase 2 clinical trial evaluating Etokimab, Placebo, and 1 other intervention for Chronic Rhinosinusitis. Completed, enrolled 105 participants across 28 sites.

Detailed Summary

A study to evaluate the safety and efficacy of multiple doses of etokimab in adults with chronic rhinosinusitis with nasal polyps.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Rhinosinusitis
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedAug 3, 2018
Enrollment StartNov 29, 2018
Primary CompletionSep 2, 2020
Study CompletionOct 26, 2020
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 7.9 years ago

Interventions

Etokimabbiological

Administered by subcutaneous injection

Placebobiological

Administered by subcutaneous injection

Mometasone Furoate Nasal Spraydrug

Mometasone Furoate Nasal Spray (MFNS) was used from 4 weeks prior to Day 1 (Run-in period) through the end of the study. Participants used 2 actuations (50 μg/actuation) in each nostril BID, total daily dose of 400 μg. Participants intolerant to BID intranasal corticosteroids (INCS) could use the lower dose regimen of 1 actuation in each nostril BID, total daily dose of 200 μg.